Jennifer A. Pietenpol
#146,443
Most Influential Person Now
Cancer researcher
Jennifer A. Pietenpol's AcademicInfluence.com Rankings
Jennifer A. Pietenpollaw Degrees
Law
#2614
World Rank
#3253
Historical Rank
Common Law
#118
World Rank
#127
Historical Rank
International Law
#642
World Rank
#796
Historical Rank
Jennifer A. Pietenpolbiology Degrees
Biology
#10662
World Rank
#14010
Historical Rank
Genetics
#1135
World Rank
#1234
Historical Rank
Molecular Biology
#1571
World Rank
#1599
Historical Rank
Download Badge
Law Biology
Jennifer A. Pietenpol's Degrees
- PhD Molecular Biology University of Texas Southwestern Medical Center
- Bachelors Biology University of Texas at Austin
Similar Degrees You Can Earn
Why Is Jennifer A. Pietenpol Influential?
(Suggest an Edit or Addition)Jennifer A. Pietenpol's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (2011) (4051)
- WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. (1994) (2076)
- Definition of a consensus binding site for p53 (1992) (2053)
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 (1993) (1530)
- TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights (1990) (947)
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (2016) (816)
- TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains (1990) (633)
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013) (576)
- Oncogenic forms of p53 inhibit p53-regulated gene expression (1992) (505)
- Oncogenic forms of p53 inhibit p53-regulated gene expression. (1992) (477)
- Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. (2002) (446)
- Sequence-specific transcriptional activation is essential for growth suppression by p53. (1994) (423)
- Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. (1990) (399)
- Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. (2014) (395)
- A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF‐β signaling (2007) (363)
- Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes (2014) (349)
- Significance of p63 amplification and overexpression in lung cancer development and prognosis. (2003) (335)
- Cell-cycle dysregulation and anticancer therapy. (2003) (310)
- The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations (2003) (309)
- Subtyping of triple‐negative breast cancer: Implications for therapy (2015) (281)
- PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors (2014) (271)
- Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. (2006) (248)
- New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity (2014) (241)
- Mitotic Phosphorylation of Bcl-2 during Normal Cell Cycle Progression and Taxol-induced Growth Arrest* (1998) (237)
- Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. (1999) (227)
- Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. (1995) (225)
- TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer (2012) (211)
- Paradoxical inhibition of solid tumor cell growth by bcl2. (1994) (207)
- The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. (2003) (205)
- Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro (2004) (203)
- p53 Signaling and cell cycle checkpoints. (2001) (203)
- Kinetics of p53 Binding to Promoter Sites In Vivo (2001) (195)
- p63: Molecular complexity in development and cancer. (2004) (194)
- p21Waf1/Cip1 Inhibition of Cyclin E/Cdk2 Activity Prevents Endoreduplication after Mitotic Spindle Disruption (1999) (191)
- TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. (1990) (188)
- p53 Regulation of G2 Checkpoint Is Retinoblastoma Protein Dependent (2000) (179)
- Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation (2010) (162)
- Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. (1993) (152)
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition (2013) (149)
- p63 and epithelial biology. (2006) (142)
- 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. (2001) (138)
- Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* (2003) (138)
- Dominant Negative p63 Isoform Expression in Head and Neck Squamous Cell Carcinoma (2004) (137)
- Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer (2013) (131)
- Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. (1991) (119)
- A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73 (2008) (109)
- TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. (1995) (108)
- p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. (2016) (106)
- Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. (1999) (105)
- Triple-negative breast cancer: molecular subtypes and new targets for therapy. (2015) (103)
- Clinical implications of molecular heterogeneity in triple negative breast cancer. (2015) (102)
- Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences (1991) (101)
- p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm (2007) (98)
- Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. (2014) (97)
- No room at the p53 inn (1993) (97)
- Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. (1998) (93)
- EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. (2015) (92)
- A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments (2015) (90)
- Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. (1992) (90)
- Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. (1997) (90)
- p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. (2000) (88)
- mTOR regulates autophagy-associated genes downstream of p73 (2009) (86)
- Patient-derived breast tumor xenografts facilitating personalized cancer therapy (2013) (86)
- The DNA binding activity of p53 displays reaction-diffusion kinetics. (2006) (83)
- Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival (2010) (83)
- IGFBP-3 Is a Direct Target of Transcriptional Regulation by ΔNp63α in Squamous Epithelium (2005) (75)
- Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner (2001) (74)
- ΔNp63α Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway* (2003) (72)
- RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells (2010) (72)
- Ultraviolet Radiation Induces Phosphorylation and Ubiquitin-Mediated Degradation of ΔNP63α (2005) (72)
- Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. (1998) (71)
- Multi-perspective quality control of Illumina exome sequencing data using QC3. (2014) (71)
- Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. (1999) (71)
- The role of transforming growth factor Β in glioma progression (2004) (70)
- Targeting mutant p53 in human tumors. (2012) (70)
- Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. (2002) (66)
- Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer (2006) (66)
- Chromatin Immunoprecipitation-Based Screen To Identify Functional Genomic Binding Sites for Sequence-Specific Transactivators (2005) (66)
- A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. (2001) (65)
- Transcriptional Programs Regulated by p63 in Normal Epithelium and Tumors (2007) (65)
- TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer (2019) (64)
- ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy (2010) (63)
- TGF-p Stimulation and Inhibition of Cell Proliferation: New Mechanistic Insights Minireview (1990) (59)
- IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. (2005) (58)
- MECHANISMS OF CELL-CYCLE CHECKPOINTS: AT THE CROSSROADS OF CARCINOGENESIS AND DRUG DISCOVERY* (2000) (57)
- Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. (2005) (57)
- Inhibition of Epidermal Growth Factor Receptor Signaling Decreases p63 Expression in Head and Neck Squamous Carcinoma Cells (2003) (56)
- Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation (2010) (56)
- Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells (2007) (55)
- Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients (2016) (54)
- The jury is in: p73 is a tumor suppressor after all. (2008) (52)
- The role of transforming growth factor beta in glioma progression. (1998) (51)
- Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer (2014) (51)
- Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control (2013) (51)
- Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. (1998) (50)
- Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. (2005) (49)
- Identification of novel Smad2 and Smad3 associated proteins in response to TGF‐β1 (2008) (49)
- Regulation of epithelial proliferation by TGF-beta. (1991) (48)
- Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. (2003) (45)
- Protein arginine methyltransferase I: Substrate specificity and role in hnRNP assembly (2002) (44)
- K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. (2000) (44)
- Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels (1997) (42)
- Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer (2016) (42)
- Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors (2020) (39)
- Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development) (2001) (39)
- Syk: a new player in the field of breast cancer (2000) (39)
- Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes (2021) (39)
- Prostate cancer serum biomarker discovery through proteomic analysis of alpha‐2 macroglobulin protein complexes (2008) (37)
- Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. (2005) (37)
- RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library (2015) (36)
- High Affinity Insertion/Deletion Lesion Binding by p53 (1999) (36)
- Head and neck cancer: meeting summary and research opportunities. (2004) (34)
- Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer (2015) (32)
- Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data (2016) (30)
- Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. (2016) (30)
- TGF beta regulation of epithelial cell proliferation: role of tumor suppressor genes. (1991) (29)
- p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton (2018) (26)
- Combined modality management of breast cancer: development of predictive markers through proteomics. (2003) (25)
- Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. (2016) (24)
- Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis (2011) (24)
- p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. (2007) (24)
- Evaluation of p63 and p73 antibodies for cross-reactivity (2009) (22)
- c-myc and pRB: Role in TGF-β1 Inhibition of Keratinocyte Proliferation (1991) (22)
- Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue (2017) (22)
- Expression of p63 and 14-3-3σ in Normal and Hyperdifferentiated Mucosa of the Upper Aerodigestive Tract (2002) (21)
- p53 and ΔNp63α differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis (2007) (20)
- A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer. (2009) (18)
- Cell Cycle Checkpoints as Therapeutic Targets (1999) (17)
- p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion (2018) (17)
- Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes (2021) (15)
- Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. (2013) (15)
- p73 regulates epidermal wound healing and induced keratinocyte programming (2019) (15)
- DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. (2009) (14)
- Tumour suppressor genes. No room at the p53 inn. (1993) (14)
- A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. (2000) (13)
- Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. (2002) (13)
- Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC) (2013) (13)
- Transforming growth factor regulation of keratinocyte growth. (1993) (13)
- Detection of internal exon deletion with exon Del (2014) (12)
- Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations (2019) (11)
- Head and Neck Cancer (2004) (10)
- Mammalian cells resistant to tumor suppressor genes. (1996) (10)
- Cell cycle‐dependent transduction of cell‐permeant Cre recombinase proteins (2003) (9)
- Cells to Microtubule Inhibitor-induced Apoptosis-S Cell Cycle Checkpoint Function Sensitizes 1 Defective G Updated (1999) (9)
- Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives (2012) (9)
- Tissue-specific expression of p73 and p63 isoforms in human tissues (2021) (7)
- c-myc and pRB: role in TGF-beta 1 inhibition of keratinocyte proliferation. (1991) (7)
- TEL and KIP 1 Define the Smallest Region of Deletions on 1 2 ~ 1 3 in Hematopoietic Malignancies (2000) (7)
- p53 family members: Similar biochemistry, Different biology (2005) (7)
- Racial/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer (2020) (6)
- PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer (MBC). (2011) (6)
- Differential effects of p53 mutants on the growth of human bronchial epithelial cells (1997) (4)
- Practicality of identifying mitochondria variants from exome and RNAseq data (2015) (4)
- Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes (2019) (3)
- Interferon alpha/beta modulation of growth-factor-stimulated mitogenicity in AKR-2B fibroblasts. (1989) (3)
- Interferon α/β modulation of growth‐factor‐stimulated mitogenicity in AKR‐2B fibroblasts (1989) (3)
- A commentary on the 1996 American Association for Cancer Research Meeting--Cancer susceptibility genes and molecular carcinogenesis. (1996) (3)
- Neoadjuvant paclitaxel/radiation for Stage II/III breast cancer with correlative molecular markers. (2004) (2)
- Regulation of Fibroblastic and Epithelial Cell Function by Transforming Growth Factors (1990) (2)
- Abstract P6-05-03: Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer (2012) (2)
- Practicality of identifying mitochondria variants from exome and RNAseq data (2015) (1)
- Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives (2012) (1)
- Abstract 5639: Preoperative concurrent paclitaxel and radiation in locally advanced breast cancer (LABC): Five-year outcomes on 105 patients (2010) (1)
- Corrigendum to “Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control” (2017) (1)
- Abstract 4928: Cyclooxygenase-1 as a target for molecular imaging of high grade serous ovarian cancer (2014) (1)
- Abstract 1518: Mechanisms of bromodomain and extra-terminal motif inhibitor (BETi) sensitivity in triple-negative breast cancer (TNBC) (2017) (1)
- Patient-derived breast tumor xenografts facilitating personalized cancer therapy (2013) (1)
- TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC). (2014) (1)
- Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC). (2010) (1)
- Detection of internal exon deletion with exon Del (2014) (1)
- A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). (2020) (1)
- p73 Is Suppressed by Cigarette Smoke and Reduced in the Lungs of Patients with Chronic Obstructive Pulmonary Disease (2022) (1)
- Abstract 531: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer (2017) (1)
- A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer (2022) (0)
- Tyramide Signal-Amplified Immunofluorescence of MYCN and MYC in Human Tissue Specimens and Cell Line Cultures. (2020) (0)
- Identification of DNA damage-dependent checkpoint kinase 1 (Chk1) posttranslational modifications and associated proteins (2004) (0)
- Five-year Local Control Results of Preoperative Paclitaxel with Concurrent Radiation Therapy in Locally Advanced Breast Cancer (2010) (0)
- Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue (2017) (0)
- Abstract 4411: γH2AX as a marker of genomic instability predicts cisplatin sensitivity in triple negative breast cancer cells (2011) (0)
- p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton (2018) (0)
- Robust biomarker discovery through multiplatform multiplex image analysis of breast cancer clinical cohorts (2023) (0)
- Abstract 4698: Gene expression profiles of triple negative breast cancer epithelial and stromal cells are predictive of treatment response. (2013) (0)
- Abstract 1178: Racial/ethnic disparities in overall mortality among patients diagnosed with triple negative breast cancer (2020) (0)
- The Role of Mitotic Events in Taxol Mediated Apoptosis in Breast Cancer Cells (2000) (0)
- Functional characterization of somatic nonsense mutations of p53 (2007) (0)
- Trend Towards Improved Survival in Triple Negative Stage II/III Breast Cancer Patients Treated With Preoperative Concurrent Paclitaxel and Radiation (2015) (0)
- Transforming Growth Factor-β Regulation of Epithelial Proliferation (1991) (0)
- Abstract 2068: Cyclooxygenase-1 gene expression contributes to multiple oncogenic pathways in high grade serous ovarian cancer (2015) (0)
- Advances in Brief WAF 1 / CIP 1 Is Induced in / ? 53-mediated G ! Arrest and Apoptosis 1 (2006) (0)
- Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype (2022) (0)
- Assignment of the Human p27Kipl Gene to 12pl3 and Its Analysis in Leukemias1 (1995) (0)
- Tumor Suppressors | p53 Family (2021) (0)
- DevelopmentofaRSKInhibitorasaNovelTherapy for Triple-Negative Breast Cancer (2016) (0)
- Abstract P6-03-04: TGF-β receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer (2015) (0)
- The Role of Chk1 Kinase in Cell Cycle Checkpoint Response in Breast Epithelial Cells (2002) (0)
- Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients (2016) (0)
- Abstract 2489: A functional genomics approach to determine mutant p53 gain-of-function mechanisms and phenotypes in tumorigenesis (2021) (0)
- A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC). (2010) (0)
- Abstract P5-09-01: Using isogenic model systems to determine mechanisms regulating mutant p53 protein stability in breast cancer cells (2022) (0)
- Abstract 6149: Prognostic tumor microenvironment subtypes in triple-negative breast cancer (2022) (0)
- S03 01 SA – TGFβ REGULATION OF CELL PROLIFERATION (1991) (0)
- Cell Cycle Manipulation in Breast Cancer: Implications for Improved Therapy. (1999) (0)
- Integration of Genomic, Biologic, and Chemical Approaches to Target p53 Loss and Gain-of-Function in Triple Negative Breast Cancer (2015) (0)
- Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients (2016) (0)
- Abstract P3-05-09: The role of TGF-beta receptor type 3 in breast cancer progression (2012) (0)
- The Role of Chk1 in Breast Epithelial Cell Checkpoint Function (2002) (0)
- Abstract P2-09-24: Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer (2018) (0)
- Abstract P6-08-04: Creation of a robust algorithm utilizing minimal gene sets normalized against a reference gene set to identify triple-negative breast cancer (TNBC) subtypes (2015) (0)
- Five-year Results of Preoperative Paclitaxel with Concurrent Radiation Therapy in Locally Advanced Breast Cancer: Pathological Response Predicts for Survival (2010) (0)
- Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes (2019) (0)
- Abstract POSTER-BIOL-1350: Dissecting cellular and molecular consequences of disrupting cyclooxygenase-1 activity in ovarian cancer (2015) (0)
- Abstract 951: Loss-of-function screening identifies therapeutic targets for triple negative breast cancer (TNBC) (2011) (0)
- Abstract ES2-2: Triple Negative Breast Cancer: Subtypes, Molecular Targets, and Therapeutic Approaches (2012) (0)
- PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors (2014) (0)
- Abstract P2-06-09: Identification of oncogenic gene fusions in triple-negative breast cancer metastatic to the brain (2019) (0)
- p73 Is Required for pIgR Expression in the Respiratory Epithelium. (2018) (0)
- Molecular classification of triple negative breast cancer (2013) (0)
- Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients (2016) (0)
- Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC). (2010) (0)
- Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer (2014) (0)
- Loss of P73 Is Common in Chronic Obstructive Pulmonary Disease Small Airways, Is Induced by Cigarette Smoke, and Contributes to Emphysema (2023) (0)
- Vivo Kinetics of p 53 Binding to Promoter Sites In (2001) (0)
- Abstract ES9-1: Adjuvant Treatment of HER2 Positive Breast Cancer: The Next Installment (2012) (0)
- Identification of transcriptional programs regulated by p63 in primary epithelial cells (2008) (0)
- Synthetic Lethal Relationships in the DNA Damage Response of Triple Negative Breast Cancer (2011) (0)
- In Vivo p53 Signaling in Breast Epithelial Cells After Oncogenic Stimulus (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jennifer A. Pietenpol?
Jennifer A. Pietenpol is affiliated with the following schools:
